Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CATALYST PHARMACEUTICALS, INC. (CPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 4 DENKHAUS DONALD A (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 60,000 options to buy @ $1.13, valued at $67.8k
07/28/2023 8-K Quarterly results
07/21/2023 8-K Quarterly results
07/17/2023 ARS Form ARS - Annual Report to Security Holders:
07/12/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/29/2023 4 Del Carmen Jeffrey (Chief Commercial Officer) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Paid exercise price by delivering 3,942 shares @ $0
Exercised 10,000 restricted stock units @ $0
06/05/2023 3 Thompson Tamar (Director) has filed a Form 3 on CATALYST PHARMACEUTICALS, INC.
06/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023"
05/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors"
05/17/2023 4 MCENANY PATRICK J (President and CEO) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Sold 26,151 shares @ $13.23, valued at $346k
Exercised 26,151 options to buy @ $0.79, valued at $20.7k
Exercised 173,849 options to buy @ $0.79, valued at $137.3k
05/16/2023 4 Daly Richard J (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 50,000 options to buy @ $0.79, valued at $39.5k
05/12/2023 4 Tierney David S (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 20,000 options to buy @ $0.79, valued at $15.8k
05/12/2023 4 Miller Steve (COO) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 100,000 options to buy @ $0.79, valued at $79k
05/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year"
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE ® From 80 mg Per Day To 100 mg Per Day"
05/05/2023 4 COELHO PHILIP H (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 50,000 shares @ $0.79, valued at $39.5k
Granted 50,000 options to buy @ $0.79, valued at $39.5k
04/24/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/24/2023 4 GRANDE ALICIA (VP, Treasurer and CFO) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Sold 3,260 shares @ $16.41, valued at $53.5k
Sold 38,524 shares @ $16.51, valued at $636k
Exercised 3,260 options to buy @ $0.79, valued at $2.6k
Exercised 38,524 options to buy @ $0.79, valued at $30.4k
03/22/2023 4 Elsbernd Brian (Chief Compliance/Legal Officer) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Sold 50,000 shares @ $16.069, valued at $803.5k
Exercised 50,000 options to buy @ $1.13, valued at $56.5k
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Other Events  Interactive Data
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 0% stake in CATALYST PHARMACEUTICALS, INC.
02/10/2023 SC 13G/A Flynn James E reports a 5.6% stake in Catalyst Pharmaceuticals, Inc.
02/08/2023 SC 13G/A STATE STREET CORP reports a 7.6% stake in AMEMDED FILING CATALYST PHARMACEUTICALS INC
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance"
01/30/2023 8-K Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® CIII"
01/27/2023 4 O'Keeffe Charles B (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 50,000 options to buy @ $0.79, valued at $39.5k
01/27/2023 4 DENKHAUS DONALD A (Director) has filed a Form 4 on CATALYST PHARMACEUTICALS, INC.
Txns: Exercised 50,000 options to buy @ $0.79, valued at $39.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy